Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
Franck E. Nicolini(Inserm), Jörge E. Cortes(Augusta University Health), Simona Soverini(University of Bologna), Giuseppe Saglio(University of Turin), Andreas Hochhaus(Jena University Hospital), Stéphane Morisset(Lyon 1 Université), Eduardo Olavarría(Universidad de Navarra), Senaka Peter(Merck & Co., Inc., Rahway, NJ, USA (United States)), Grzegorz Basak(Medical University of Warsaw), Gabriel Étienne(Institut Bergonié), Mauricette Michallet(Université Claude Bernard Lyon 1), Giovanni Martinelli(University of Bologna), Jane F. Apperley(Hammersmith Hospital), Charles Chuah(SingHealth), Giovanna Rege‐Cambrin, Martin C. Müller(Universität Hamburg), Inge Høgh Dufva(University of Copenhagen), Wei Zhou(Broad Institute), Sandrine Hayette(Hôpital Claude Huriez), Hélène Labussière(Hôpital Lyon Sud), Michael J. Mauro(Memorial Sloan Kettering Cancer Center)
Cited by 61
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k